ACLY在糖脂代谢中的机制研究
Mechanism of ACLY in Glucose and Lipid Metabolism
DOI: 10.12677/acm.2026.1641524, PDF,    科研立项经费支持
作者: 袁乐怡：西安医学院研究生工作部，陕西 西安；王 彤, 余 州, 宋保强*：空军军医大学西京医院整形外科，陕西 西安
关键词: ACLY；糖脂代谢；乙酰辅酶A；ACLY； Glucose and Lipid Metabolism； Acetyl-CoA
摘要: 糖脂代谢是维持机体能量稳态的核心生命活动，其动态平衡对于机体适应内外环境变化至关重要。ATP-柠檬酸裂解酶(ATP Citrate Lyase, ACLY)是细胞代谢的核心调控酶，通过催化葡萄糖分解与脂肪生成的关键限速反应，在糖代谢与脂质合成之间架起重要桥梁。研究表明，ACLY调节细胞增殖和代谢，与多种代谢性疾病的病理进程密切相关。本文系统综述ACLY的蛋白结构特征、生物学功能及其表达调控机制，重点阐述其在糖脂代谢中的调控作用与分子机制。同时，结合ACLY抑制剂在代谢性疾病治疗中的研究进展，以期为糖脂代谢紊乱相关疾病的机制研究和靶向治疗提供理论依据。
Abstract: Glucolipid metabolism is a core life activity that maintains systemic energy homeostasis, and its dynamic balance is essential for the body to adapt to changes in both internal and external environments. ATP citrate lyase (ACLY) serves as a pivotal regulatory enzyme in cellular metabolism, bridging glucose metabolism and lipid synthesis by catalyzing a key rate-limiting reaction that links glycolysis to fat production. Recent studies have shown that ACLY regulates cell proliferation and metabolism and is closely associated with the pathological progression of various metabolic diseases. This review systematically summarizes the structural characteristics, biological functions, and expression regulatory mechanisms of the ACLY with a focus on its regulatory role and molecular mechanisms in glucose and lipid metabolism. Additionally, we discuss the research progress of ACLY inhibitors in the treatment of metabolic diseases, aiming to provide a theoretical basis for mechanistic studies and targeted therapies for disorders associated with glucose and lipid metabolism disorders.
文章引用：袁乐怡, 王彤, 余州, 宋保强. ACLY在糖脂代谢中的机制研究[J]. 临床医学进展, 2026, 16(4): 2701-2709. https://doi.org/10.12677/acm.2026.1641524

参考文献

[1] Khwairakpam, A.D., Banik, K., Girisa, S., Shabnam, B., Shakibaei, M., Fan, L., et al. (2020) The Vital Role of ATP Citrate Lyase in Chronic Diseases. Journal of Molecular Medicine, 98, 71-95. [Google Scholar] [CrossRef] [PubMed]
[2] Batchuluun, B., Pinkosky, S.L. and Steinberg, G.R. (2022) Lipogenesis Inhibitors: Therapeutic Opportunities and Challenges. Nature Reviews Drug Discovery, 21, 283-305. [Google Scholar] [CrossRef] [PubMed]
[3] Feng, X., Zhang, L., Xu, S. and Shen, A. (2020) ATP-Citrate Lyase (ACLY) in Lipid Metabolism and Atherosclerosis: An Updated Review. Progress in Lipid Research, 77, Article ID: 101006. [Google Scholar] [CrossRef] [PubMed]
[4] Icard, P., Wu, Z., Fournel, L., Coquerel, A., Lincet, H. and Alifano, M. (2020) ATP Citrate Lyase: A Central Metabolic Enzyme in Cancer. Cancer Letters, 471, 125-134. [Google Scholar] [CrossRef] [PubMed]
[5] Granchi, C. (2018) ATP Citrate Lyase (ACLY) Inhibitors: An Anti-Cancer Strategy at the Crossroads of Glucose and Lipid Metabolism. European Journal of Medicinal Chemistry, 157, 1276-1291. [Google Scholar] [CrossRef] [PubMed]
[6] Bradshaw, P.C. (2021) Acetyl-Coa Metabolism and Histone Acetylation in the Regulation of Aging and Lifespan. Antioxidants, 10, Article 572. [Google Scholar] [CrossRef] [PubMed]
[7] Infantino, V., Santarsiero, A., Convertini, P., Todisco, S. and Iacobazzi, V. (2021) Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. International Journal of Molecular Sciences, 22, Article 5703. [Google Scholar] [CrossRef] [PubMed]
[8] Gao, W., Zhang, L., Li, Z., Wu, T., Lang, C., Mulholland, M.W., et al. (2024) Nuclear Acly Protects the Liver from Ischemia-Reperfusion Injury. Hepatology, 80, 1087-1103. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, M., Ji, J., Lei, Y., Qin, F., Tao, Y., Li, N., et al. (2025) Dual Inhibition of Hepatic ACLY and ACSS2: A Synergistic Approach to Combat NAFLD through Lipogenesis Reduction and Mitochondrial Enhancement. Pharmacological Research, 215, Article ID: 107706. [Google Scholar] [CrossRef] [PubMed]
[10] Fei, X., Huang, J., Li, F., Wang, Y., Shao, Z., Dong, L., et al. (2023) The Scap-SREBP1-S1P/S2P Lipogenesis Signal Orchestrates the Homeostasis and Spatiotemporal Activation of NF-κB. Cell Reports, 42, Article ID: 112586. [Google Scholar] [CrossRef] [PubMed]
[11] Zaidi, N., Swinnen, J.V. and Smans, K. (2012) ATP-Citrate Lyase: A Key Player in Cancer Metabolism. Cancer Research, 72, 3709-3714. [Google Scholar] [CrossRef] [PubMed]
[12] Dominguez, M., Brüne, B. and Namgaladze, D. (2021) Exploring the Role of ATP-Citrate Lyase in the Immune System. Frontiers in Immunology, 12, Article 632526. [Google Scholar] [CrossRef] [PubMed]
[13] Su, F. and Koeberle, A. (2024) Regulation and Targeting of SREBP-1 in Hepatocellular Carcinoma. Cancer and Metastasis Reviews, 43, 673-708. [Google Scholar] [CrossRef] [PubMed]
[14] Iizuka, K., Takao, K. and Yabe, D. (2020) ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue. Frontiers in Endocrinology, 11, Article 587189. [Google Scholar] [CrossRef] [PubMed]
[15] Pinweha, P., Rattanapornsompong, K., Charoensawan, V. and Jitrapakdee, S. (2016) MicroRNAs and Oncogenic Transcriptional Regulatory Networks Controlling Metabolic Reprogramming in Cancers. Computational and Structural Biotechnology Journal, 14, 223-233. [Google Scholar] [CrossRef] [PubMed]
[16] He, B., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., et al. (2020) miRNA-Based Biomarkers, Therapies, and Resistance in Cancer. International Journal of Biological Sciences, 16, 2628-2647. [Google Scholar] [CrossRef] [PubMed]
[17] Li, G., Li, M., Hu, J., Lei, R., Xiong, H., Ji, H., et al. (2017) The MicroRNA-182-PDK4 Axis Regulates Lung Tumorigenesis by Modulating Pyruvate Dehydrogenase and Lipogenesis. Oncogene, 36, 989-998. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, M., Li, L., Liu, R., Song, Y., Zhang, X., Niu, W., et al. (2018) Obesity-Induced Overexpression of miRNA-24 Regulates Cholesterol Uptake and Lipid Metabolism by Targeting SR-B1. Gene, 668, 196-203. [Google Scholar] [CrossRef] [PubMed]
[19] Cheng, Y., Jia, B., Wang, Y. and Wan, S. (2017) MiR-133b Acts as a Tumor Suppressor and Negatively Regulates ATP Citrate Lyase via PPARγ in Gastric Cancer. Oncology Reports, 38, 3220-3226. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, X., Xu, Y., Li, S., Qin, Y., Zhu, G., Zhang, Q., et al. (2024) SIRT2‐Mediated Deacetylation of ACLY Promotes the Progression of Oesophageal Squamous Cell Carcinoma. Journal of Cellular and Molecular Medicine, 28, e18129. [Google Scholar] [CrossRef] [PubMed]
[21] Sivanand, S., Rhoades, S., Jiang, Q., Lee, J.V., Benci, J., Zhang, J., et al. (2017) Nuclear Acetyl-Coa Production by ACLY Promotes Homologous Recombination. Molecular Cell, 67, 252-265.e6. [Google Scholar] [CrossRef] [PubMed]
[22] Tian, M., Hao, F., Jin, X., Sun, X., Jiang, Y., Wang, Y., et al. (2021) ACLY Ubiquitination by CUL3-KLHL25 Induces the Reprogramming of Fatty Acid Metabolism to Facilitate iTreg Differentiation. eLife, 10, e62394. [Google Scholar] [CrossRef] [PubMed]
[23] Seyfried, T.N., Lee, D.C., Duraj, T., Ta, N.L., Mukherjee, P., Kiebish, M., et al. (2025) The Warburg Hypothesis and the Emergence of the Mitochondrial Metabolic Theory of Cancer. Journal of Bioenergetics and Biomembranes, 57, 57-83. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, J., Wang, Y., Tian, M., Xia, M., Zheng, Y., Hao, M., et al. (2024) o-Glcnacylation of ATP-Citrate Lyase Couples Glucose Supply to Lipogenesis for Rapid Tumor Cell Proliferation. Proceedings of the National Academy of Sciences of the United States of America, 121, e2402674121. [Google Scholar] [CrossRef] [PubMed]
[25] Paul, B., Lewinska, M. and Andersen, J.B. (2022) Lipid Alterations in Chronic Liver Disease and Liver Cancer. JHEP Reports, 4, Article ID: 100479. [Google Scholar] [CrossRef] [PubMed]
[26] (2015) Coenzyme Q10 and Statin-Related Myopathy. Drug and Therapeutics Bulletin, 53, 54-56. [Google Scholar] [CrossRef] [PubMed]
[27] Stine, Z.E., Schug, Z.T., Salvino, J.M. and Dang, C.V. (2022) Targeting Cancer Metabolism in the Era of Precision Oncology. Nature Reviews Drug Discovery, 21, 141-162. [Google Scholar] [CrossRef] [PubMed]
[28] Xiang, W., Lv, H., Xing, F., Sun, X., Ma, Y., Wu, L., et al. (2023) Inhibition of ACLY Overcomes Cancer Immunotherapy Resistance via Polyunsaturated Fatty Acids Peroxidation and cGAS-STING Activation. Science Advances, 9, eadi2465. [Google Scholar] [CrossRef] [PubMed]
[29] Morrow, M.R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J.M., Mohammadi-Shemirani, P., et al. (2022) Inhibition of ATP-Citrate Lyase Improves NASH, Liver Fibrosis, and Dyslipidemia. Cell Metabolism, 34, 919-936.e8. [Google Scholar] [CrossRef] [PubMed]
[30] Gao, Y., Islam, M.S., Tian, J., Lui, V.W.Y. and Xiao, D. (2014) Inactivation of ATP Citrate Lyase by Cucurbitacin B: A Bioactive Compound from Cucumber, Inhibits Prostate Cancer Growth. Cancer Letters, 349, 15-25. [Google Scholar] [CrossRef] [PubMed]
[31] Ruscica, M., Sirtori, C.R., Carugo, S., Banach, M. and Corsini, A. (2022) Bempedoic Acid: For Whom and When. Current Atherosclerosis Reports, 24, 791-801. [Google Scholar] [CrossRef] [PubMed]
[32] Nissen, S.E., Lincoff, A.M., Brennan, D., Ray, K.K., Mason, D., Kastelein, J.J.P., et al. (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine, 388, 1353-1364. [Google Scholar] [CrossRef] [PubMed]
[33] Desjardins, E.M., Wu, J., Lavoie, D.C.T., Ahmadi, E., Townsend, L.K., Morrow, M.R., et al. (2023) Combination of an ACLY Inhibitor with a GLP-1R Agonist Exerts Additive Benefits on Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Mice. Cell Reports Medicine, 4, Article ID: 101193. [Google Scholar] [CrossRef] [PubMed]
[34] Pinkosky, S.L., Newton, R.S., Day, E.A., Ford, R.J., Lhotak, S., Austin, R.C., et al. (2016) Liver-Specific ATP-Citrate Lyase Inhibition by Bempedoic Acid Decreases LDL-C and Attenuates Atherosclerosis. Nature Communications, 7, Article No. 13457. [Google Scholar] [CrossRef] [PubMed]
[35] Nikolic, D., Mikhailidis, D.P., Davidson, M.H., Rizzo, M. and Banach, M. (2014) ETC-1002: A Future Option for Lipid Disorders? Atherosclerosis, 237, 705-710. [Google Scholar] [CrossRef] [PubMed]
[36] Wei, J., Leit, S., Kuai, J., Therrien, E., Rafi, S., Harwood, H.J., et al. (2019) An Allosteric Mechanism for Potent Inhibition of Human ATP-Citrate Lyase. Nature, 568, 566-570. [Google Scholar] [CrossRef] [PubMed]
[37] Zheng, Y., Zhou, Q., Zhao, C., Li, J., Yu, Z. and Zhu, Q. (2021) ATP Citrate Lyase Inhibitor Triggers Endoplasmic Reticulum Stress to Induce Hepatocellular Carcinoma Cell Apoptosis via p‐eIF2α/ATF4/CHOP Axis. Journal of Cellular and Molecular Medicine, 25, 1468-1479. [Google Scholar] [CrossRef] [PubMed]
[38] Wang, Y., Tang, B., Long, L., Luo, P., Xiang, W., Li, X., et al. (2021) Improvement of Obesity-Associated Disorders by a Small-Molecule Drug Targeting Mitochondria of Adipose Tissue Macrophages. Nature Communications, 12, Article No. 102. [Google Scholar] [CrossRef] [PubMed]
[39] Zeng, H., Qin, H., Liao, M., Zheng, E., Luo, X., Xiao, A., et al. (2022) CD36 Promotes De Novo Lipogenesis in Hepatocytes through INSIG2-Dependent SREBP1 Processing. Molecular Metabolism, 57, Article ID: 101428. [Google Scholar] [CrossRef] [PubMed]
[40] Ference, B.A., Ray, K.K., Catapano, A.L., Ference, T.B., Burgess, S., Neff, D.R., et al. (2019) Mendelian Randomization Study of ACLY and Cardiovascular Disease. The New England Journal of Medicine, 380, 1033-1042. [Google Scholar] [CrossRef] 
[41] Baardman, J., Verberk, S.G.S., van der Velden, S., Gijbels, M.J.J., van Roomen, C.P.P.A., Sluimer, J.C., et al. (2020) Macrophage ATP Citrate Lyase Deficiency Stabilizes Atherosclerotic Plaques. Nature Communications, 11, Article No. 6296. [Google Scholar] [CrossRef] [PubMed]
[42] Ma, Y., Zhang, Y., Yang, W., Tong, X., Liu, S., Zhou, Y., et al. (2025) The Nuclear Localization of ACLY Guards Early Embryo Development through Recruiting P300 and HAT1 to Promote Histone Acetylation and Transcription. Advanced Science, 12, e14367. [Google Scholar] [CrossRef] [PubMed]

为你推荐